By Kelly Knaub ( October 20, 2015, 4:41 PM EDT) -- The Patent Trial and Appeal Board has denied another petition by an organization tied to hedge fund manager Kyle Bass for an inter partes review of a patent on Pharmacyclics Inc.'s cancer drug Imbruvica, saying it failed to establish it would likely succeed in showing the claims are unpatentable....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.